within Pharmacolibrary.Drugs.ATC.L;

model L01XH01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.43,
    Cl             = 0.19 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 400 / 1000000,
    adminCount     = 1,
    Vd             = 0.0005,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.008166666666666666,
    Tlag           = 10.200000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Vorinostat is a histone deacetylase inhibitor used as an antineoplastic agent primarily for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent, or recurrent disease on or following two systemic therapies. It is approved for use in several countries including the United States.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult patients with advanced cancer after oral administration. Data represent typical values in studied populations.</p><h4>References</h4><ol><li><p>Kavanaugh, SM, et al., &amp; Kolesar, JM (2010). Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma. <i>American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists</i> 67(10) 793–797. DOI:<a href=&quot;https://doi.org/10.2146/ajhp090247&quot;>10.2146/ajhp090247</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/20479100/&quot;>https://pubmed.ncbi.nlm.nih.gov/20479100</a></p></li><li><p>Rubin, EH, et al., &amp; Iwamoto, M (2006). A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer. <i>Clinical cancer research : an official journal of the American Association for Cancer Research</i> 12(23) 7039–7045. DOI:<a href=&quot;https://doi.org/10.1158/1078-0432.CCR-06-1802&quot;>10.1158/1078-0432.CCR-06-1802</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17145826/&quot;>https://pubmed.ncbi.nlm.nih.gov/17145826</a></p></li><li><p>Kang, SP, et al., &amp; Ratain, MJ (2010). A pharmacogenetic study of vorinostat glucuronidation. <i>Pharmacogenetics and genomics</i> 20(10) 638–641. DOI:<a href=&quot;https://doi.org/10.1097/FPC.0b013e32833e1b37&quot;>10.1097/FPC.0b013e32833e1b37</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/20729791/&quot;>https://pubmed.ncbi.nlm.nih.gov/20729791</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01XH01;
